Effect of autologous bone marrow-derived mesenchymal stem cells on portal hemodynamics in patients with liver cirrhosis

• Main Author: SHANG Jianzhong
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2013-11-01
• Series: Linchuang Gandanbing Zazhi
• Subjects: mesenchymal stem cells transplantation; hypertension; portal; liver cirrhosis; hemodynamics
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=5542&ClassID=10149522

ObjectiveTo observe the effect of autologous bone marrow-derived mesenchymal stem cells (BMMSCs) on the portal hemodynamics in patients with hepatitis B virus (HBV)-related decompensated cirrhosis. Methods Forty-six patients with HBV-related decompensated cirrhosis, who were admitted to the hospital from February 2011 to January 2012, were divided into treatment group (n=23) and control group (n=23). There were no significant differences in sex, age, diagnosis, biochemical parameters, and imaging findings between the two groups. All patients provided informed consent prior to treatment. Both groups received antiviral, liver-protecting, and diuretic treatment. In addition, in the treatment group, bone marrow (200 ml) was drawn from each patient, BMMSCs were isolated, purified, and cultured, and the cultured cells were processed into cell suspension (10 ml); the cell suspension was injected into the liver via the hepatic artery. After 8 and 12 weeks of treatment, the changes in portal hemodynamic parameters were evaluated. The obtained data were analyzed using SPSS 13.0 software; the paired t test was used for within-group comparisons. ResultsAfter 8 and 12 weeks of treatment, in the treatment group, the diameter of portal vein (DPV) was significantly decreased to 13.26±1.31 mm (t=2.290, P＜0.05) and 12.83±138 mm (t=3.421, P＜0.01), and the diameter of splenic vein (DSV) was significantly decreased to 8.39±1.38 mm (t=2.079, P＜0.05) and 8.02±1.24 mm (t=2.787, P＜0.01); compared with the control group, the treatment group had significantly lower DPV (t=2.382, P＜0.05; t=2.602, P＜0.05) and DSV (t=3.236, P＜0.01; t=4.185, P＜0.01). After 8 and 12 weeks of treatment, in the treatment group, the portal vein maximum velocity (PVX) was significantly increased to 2072±463 cm/s (t=2.833, P＜0.01) and 2058±346 cm/s (t=3.198, P＜0.01); compared with the control group, the treatment group had significantly higher PVX (t=2.530, P＜0.05; t=3.123, P＜0.01). ConclusionAutologous BMMSCs can significantly improve the portal hemodynamics in patients with HBV-related decompensated cirrhosis.